Chinthanie Ramasundarahettige Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2023	Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
1/2022	A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
1/2022	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
1/2021	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chinthanie Ramasundarahettige Research Topics

Disease

7	Stroke (Strokes) 10/2023 - 07/2018
4	Myocardial Infarction 01/2023 - 10/2020
4	Type 2 Diabetes Mellitus (MODY) 01/2023 - 01/2021
3	Kidney Diseases (Kidney Disease) 12/2023 - 01/2021
3	Heart Failure 01/2023 - 11/2017
3	Atrial Fibrillation 01/2022 - 01/2018
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2019
2	Peripheral Arterial Disease 01/2023 - 01/2021
2	Unstable Angina 01/2023 - 01/2022
2	Body Weight (Weight, Body) 01/2022 - 01/2021
2	Neoplasms (Cancer) 01/2022 - 10/2013
2	Vascular Diseases (Vascular Disease) 12/2021 - 01/2021
1	Cognitive Dysfunction 01/2024
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023
1	Renal Insufficiency (Renal Failure) 01/2023
1	Atherosclerosis 10/2022
1	Venous Thromboembolism 01/2022
1	Obesity 01/2022
1	Rheumatic Heart Disease (Rheumatic Heart Diseases) 01/2022
1	Hemorrhage 01/2022
1	Heart Valve Diseases (Valvular Heart Disease) 12/2021
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 12/2021
1	Diarrhea 01/2021
1	Constipation 01/2021
1	Nausea 01/2021
1	Vomiting 01/2021
1	Overweight 01/2021
1	Eczema 01/2020
1	Hypertension (High Blood Pressure) 01/2019
1	Atrial Flutter (Flutter, Atrial) 01/2018

Drug/Important Bio-Agent (IBA)

5	omega-Chloroacetophenone (Mace)IBA 12/2023 - 01/2021
4	efpeglenatideIBA 12/2023 - 01/2021
3	AnticoagulantsIBA 10/2023 - 07/2018
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2023 - 01/2021
3	CreatinineIBA 01/2022 - 12/2021
2	RivaroxabanIBA 01/2022 - 01/2021
2	LipidsIBA 01/2022 - 10/2020
2	AlbuminsIBA 01/2022 - 01/2022
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2024
1	Insulin (Novolin)FDA Link 01/2024
1	Insulin Glargine (Lantus)FDA Link 01/2024
1	dulaglutideIBA 10/2022
1	Vitamin K FDA Link 01/2022
1	Rosuvastatin Calcium (Crestor)FDA Link 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Factor Xa InhibitorsIBA 01/2022
1	LDL CholesterolIBA 01/2022
1	SodiumIBA 01/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021
1	Colchicine FDA LinkGeneric 01/2018
1	ORALIT (ORS)IBA 10/2013

Therapy/Procedure

5	Therapeutics 10/2023 - 07/2018
1	Injections 01/2022
1	Subcutaneous Injections 01/2021
1	Plant-Based Diet 01/2020
1	Secondary Prevention 01/2019
1	Transitional Care 11/2017